Menu
Back to Blog
research 10 min read

FDA-Approved Since 1997: The 27-Year History of Gel Injections for Arthritis

Gel injections for arthritis have been FDA-approved since 1997. Explore the 27-year history of hyaluronic acid injections, from Hyalgan to HYMOVIS ONE, with 50+ million doses administered worldwide.

By Joint Pain Authority Team

FDA-Approved Since 1997: The 27-Year History of Gel Injections for Arthritis

The Bottom Line

Hyaluronic acid gel injections are not new, experimental, or unproven. Here’s what 27 years of FDA oversight tells us:

  • First FDA approval: May 1997 (Hyalgan)
  • Over 50 million doses of Hyalgan alone administered worldwide
  • 110+ clinical trials conducted on viscosupplementation
  • 15+ FDA-approved brands currently available in the US
  • Zero product withdrawals for safety concerns
  • Medicare coverage maintained continuously since approval

Introduction: This Treatment Has a Longer History Than Most Medications You Take

When patients hear about “gel shots” or viscosupplementation for knee arthritis, many assume it’s a newer, unproven treatment. Some worry they’re being offered something experimental.

The reality is quite different.

Hyaluronic acid injections received their first FDA approval in May 1997—the same year the first Harry Potter book was published and Tiger Woods won his first Masters. Nearly three decades later, these injections have one of the longest safety track records of any arthritis treatment still in use today.

This isn’t a treatment looking for evidence. It’s a treatment backed by 27 years of real-world use, 110+ clinical trials, and continuous FDA post-market surveillance.


The First FDA Approvals (1997)

May 1997: Hyalgan Leads the Way

May 1997: Hyalgan (Fidia Pharma) becomes the first hyaluronic acid injection approved by the FDA for knee osteoarthritis

Hyalgan’s approval marked a turning point for arthritis treatment in America. The product had already been used successfully in Europe and other countries, and FDA approval opened the door for US patients to access this non-surgical option.

August 1997: Synvisc Follows

August 1997: Synvisc (now Sanofi) receives FDA approval, offering a cross-linked, higher molecular weight formulation

Within months of Hyalgan’s approval, Synvisc entered the market with a different approach—a cross-linked hyaluronic acid designed to provide longer-lasting joint lubrication.

These two 1997 approvals established viscosupplementation as a legitimate, FDA-regulated treatment category that would grow significantly over the following decades.


The Evolution of Formulations

The Multi-Injection Era (1997-2009)

Early hyaluronic acid products required a series of injections—typically 3 to 5 weekly visits—to complete a treatment course. While effective, this created challenges for patients with transportation difficulties, busy schedules, or limited access to healthcare facilities.

Early FDA Approvals:

YearProductManufacturerSchedule
1997HyalganFidia5 injections
1997SynviscSanofi3 injections
2001SupartzBioventus3-5 injections
2004OrthoviscAnika3-4 injections
2004EuflexxaFerring3 injections

The Single-Dose Revolution (2009-Present)

In 2009, Synvisc-One changed the treatment landscape by delivering the full therapeutic dose in a single injection. This innovation dramatically improved convenience for patients and opened viscosupplementation to those who couldn’t commit to multiple weekly visits.

Single-Injection Approvals:

YearProductManufacturerInnovation
2009Synvisc-OneSanofiFirst single-injection option
2011Gel-OneZimmerCross-linked, single-dose
2014MonoviscAnikaHigh molecular weight, single
2017DurolaneBioventusBacterial fermentation, single
2025HYMOVIS ONEFidiaApril 2025 approval

Current FDA-Approved Products

A Comprehensive Landscape

Today, patients and physicians have access to 15+ FDA-approved hyaluronic acid injection brands, offering a range of formulations, molecular weights, and treatment schedules.

Currently Available FDA-Approved HA Products:

Single-Injection Products:

  • Synvisc-One (Sanofi)
  • Monovisc (Anika)
  • Durolane (Bioventus)
  • Gel-One (Zimmer)
  • HYMOVIS ONE (Fidia) - Approved April 2025

Multi-Injection Products:

  • Hyalgan (Fidia) - 5 injections
  • Synvisc (Sanofi) - 3 injections
  • Supartz FX (Bioventus) - 3-5 injections
  • Euflexxa (Ferring) - 3 injections
  • Orthovisc (Anika) - 3-4 injections
  • HYMOVIS (Fidia) - 2 injections Approved 2015
  • Visco-3 (Anika) - 3 injections

Why So Many Options?

The variety of FDA-approved products reflects different approaches to the same goal: restoring joint lubrication. Products vary by:

Molecular weight: Ranges from 500-730 kDa (low) to 6,000+ kDa (high/cross-linked)
Injection schedule: Single-dose to 5-injection series
Source material: Avian (rooster comb) or bacterial fermentation
Cross-linking: Some formulations are chemically stabilized for longer residence time

Manufacturing: Rooster Comb vs. Bacterial Fermentation

Two Approaches, Same Goal

HA injections are manufactured using one of two methods, each with distinct characteristics:

Avian-Derived (Rooster Comb Extraction):

Extracted from rooster combs (the fleshy crest on a rooster’s head)
Products: Synvisc, Synvisc-One, Hyalgan, Supartz FX, Orthovisc, Gel-One
Consideration: Patients with bird or egg allergies should discuss with their doctor

Bacterial Fermentation (Non-Avian):

Produced by genetically engineered bacteria (typically Streptococcus species)
Products: Euflexxa, Monovisc, Durolane
Advantage: Safe for patients with bird/egg allergies

Which Is Better?

Clinical studies show no significant difference in effectiveness between avian-derived and fermented products. The choice primarily matters for patients with specific allergies. Both manufacturing methods produce pharmaceutical-grade hyaluronic acid that meets FDA standards.


The 27-Year Safety Record

What Continuous FDA Oversight Means

MAUDE Database Monitoring: The FDA continuously collects adverse event reports
No Black Box Warnings: Unlike NSAIDs, HA injections carry no FDA black box warnings
No Product Withdrawals: No HA injection has been withdrawn for safety reasons
Continued Medicare Coverage: CMS has maintained coverage since 1997, affirming medical necessity
New Products Still Being Approved: HYMOVIS ONE approved as recently as April 2025

By the Numbers

27 Years of Evidence:

MetricData Point
Years of FDA approval27+ years (since 1997)
Hyalgan doses worldwide50+ million
Clinical trials conducted110+
FDA-approved brands15+
Black box warningsZero
Products withdrawn for safetyZero

What This Means for You

Reassurance for the Skeptical Patient

If you’ve been hesitant about gel injections because they seem “new” or “experimental,” the evidence tells a different story:

Your doctor is recommending a treatment with nearly three decades of FDA oversight
Medicare has covered these injections continuously since 1997
Over 50 million doses of just one brand (Hyalgan) have been administered globally
More than 110 clinical trials have studied viscosupplementation

Questions to Ask Your Doctor

If you’re considering gel injections, the history of FDA approval shouldn’t be a concern. Better questions to discuss with your provider include:

  1. Which specific product do you recommend for my situation?
  2. Is a single-injection or series right for me?
  3. Do you use imaging guidance (fluoroscopy or ultrasound) for injection accuracy?
  4. What results have your patients typically experienced?
  5. How does my insurance cover this treatment?

Frequently Asked Questions

Are gel injections FDA-approved?

Yes. Hyaluronic acid injections have been FDA-approved since May 1997, when Hyalgan received the first approval. Today, 15+ brands are FDA-approved for knee osteoarthritis.

How long have gel injections been available?

Hyaluronic acid injections have been available in the United States for 27 years, since their first FDA approval in 1997. They were used in Europe even earlier.

Are these injections considered experimental?

No. With 27 years of FDA approval, 110+ clinical trials, and over 50 million doses of Hyalgan alone administered worldwide, viscosupplementation is a well-established treatment with extensive real-world evidence.

Why are there so many different brands?

Multiple manufacturers have developed different formulations to address various patient needs—single-dose convenience, different molecular weights, and options for patients with bird allergies (fermented products). All FDA-approved brands meet rigorous safety and efficacy standards.

Does Medicare cover gel injections?

Yes. Medicare Part B has covered hyaluronic acid injections for knee osteoarthritis continuously since 1997 when medically necessary. Coverage requires a diagnosis of knee OA and typically documentation of failed conservative treatment.

Which came first—Synvisc or Hyalgan?

Hyalgan was FDA-approved first (May 1997), followed by Synvisc (August 1997). Both have been available for over 27 years.


Find an Experienced Provider

Locate providers who offer FDA-approved gel injections with imaging guidance for optimal results.

Imaging-Guided Medicare Accepted

Used to find providers in your area

Required to submit this form

Your information is secure. See our Privacy Policy and Terms of Service.

Thank You!

We've received your request. A provider specialist will contact you within 1-2 business days to help you find the right care.

What happens next?

  • 1 We'll verify your insurance coverage
  • 2 Match you with quality providers in your area
  • 3 Contact you to discuss your options

Questions? Browse our guides:

How to Choose a Provider

References

  1. FDA Premarket Approval Database. Device Approvals for Viscosupplementation Products. FDA

  2. Fidia Pharma USA. Hyalgan Prescribing Information and Clinical Data.

  3. Sanofi. Synvisc and Synvisc-One Product History and Prescribing Information.

  4. FDA MAUDE Database. Post-Market Surveillance for Viscosupplementation Devices. FDA MAUDE

  5. Centers for Medicare & Medicaid Services. National Coverage Determination for Viscosupplementation.

Stay Informed About Joint Pain Treatments

Get evidence-based updates on arthritis treatments, Medicare coverage, and the latest research.

You're in! Check your inbox.

Join 10,000+ readers. No spam.


Treatment Overview

Insurance and Coverage

Brand Information

Enjoyed this article?

Get more insights like this delivered to your inbox weekly.

You're in! Check your inbox.

Join 10,000+ readers. No spam.

Your Next Steps

What's Your Next Step?

You've learned about fda-approved since 1997: the 27-year history of gel injections for arthritis. Here's how to move forward:

Have questions? Contact us or call 1-800-555-0123